CTLA4 and hypophysitis: Gastrointestinal inflammation and hypophysitis are more common with CTLA‐4 blockade, while thyroiditis, pneumonitis, and autoimmune diabetes are more commonly associated with PD‐1 blockade [8, 17, 18].